Ozempic: The Diabetes Drug Turned Weight Loss Sensation

GLP-1 Agonists: From Blood Sugar Control to Appetite Suppression

Ozempic (semaglutide) belongs to the class of GLP-1 receptor agonists, drugs that mimic a gut hormone responsible for regulating insulin secretion and appetite. Originally approved by the FDA in 2017 for type 2 diabetes, its weight loss effects were discovered serendipitously. Patients in clinical trials reported substantial reductions in body weight, a finding later confirmed in dedicated obesity trials. The drug slows gastric emptying and signals satiety to the brain, reducing caloric intake by 20–30% on average.

In the STEP 1 trial, participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo.

The mechanism is elegant but not without complexity. GLP-1 receptors are expressed not only in the pancreas but also in the brainstem and hypothalamus, areas that regulate reward and feeding behavior. This dual action — enhancing insulin release and curbing appetite — makes semaglutide uniquely effective for weight management. Yet the drug’s success has sparked a cultural and medical phenomenon far beyond its original indication.

• Ozempic is injected once weekly; a higher-dose version (Wegovy) was approved specifically for weight loss in 2021.
• GLP-1 drugs have been shown to reduce cardiovascular events in diabetic patients, adding to their appeal.
• The class includes liraglutide (Saxenda) and newer dual agonists like tirzepatide (Mounjaro) that target both GIP and GLP-1 receptors.